Lixisenatide

What is Lixisenatide?

Lixisenatide (brand name ADLYXIN in the US, LYXUMIA in Europe and most other markets; development code AVE0010 / ZP10) is a once-daily short-acting GLP-1 receptor agonist developed by Zealand Pharma and licensed to Sanofi. It was approved by the FDA on July 27, 2016 for type 2 diabetes mellitus.

Sanofi discontinued US commercial sales in 2023 for business reasons (low market share against once-weekly GLP-1 agonists). The drug remains marketed in many other countries as Lyxumia and as the lixisenatide component of Soliqua/Suliqua (a fixed-dose combination of insulin glargine plus lixisenatide).

Structure

Lixisenatide is a synthetic 44-amino-acid peptide based on the exendin-4 backbone (the same parent molecule as exenatide), with a key modification: a C-terminal six-residue lysine extension and proline removal (replacement of Pro38-NH2 with a six-lysine tail). This modification:

• Extends plasma half-life modestly (~3 hours, supporting once-daily dosing)
• Confers slight differences in receptor pharmacology vs exenatide
• Distinguishes lixisenatide from exenatide as a separate FDA-approved peptide

Mechanism of Action

Like all GLP-1 receptor agonists, lixisenatide:

• Glucose-dependent insulin secretion from pancreatic β-cells
• Suppression of postprandial glucagon from α-cells
• Slowed gastric emptying — particularly pronounced with short-acting GLP-1 agonists, which produce ongoing meal-related delay rather than the tachyphylaxis seen with long-acting agents
• Modest appetite suppression via central GLP-1R signaling

The pharmacokinetic profile (single peak around mealtime when dosed before breakfast) makes lixisenatide more of a postprandial glucose modulator than an HbA1c sledgehammer — a niche that overlaps with mealtime insulin and rapid-onset GLP-1s.

Clinical Evidence

ELIXA Cardiovascular Outcomes Trial (NEJM 2015):

• 6,068 patients with T2D and recent ACS, randomized to lixisenatide vs placebo
• Primary outcome (CV death, MI, stroke, unstable angina hospitalization): HR 1.02 — non-inferior to placebo, neither cardioprotective nor harmful
• Notable as the first dedicated CV outcomes trial in the GLP-1 class

GetGoal Phase 3 program (multiple trials):

• Lixisenatide as monotherapy or add-on to oral agents/insulin
• HbA1c reductions of 0.5-1.0% over 24 weeks
• Modest weight loss (1-2 kg)
• Significantly improved postprandial glucose vs comparators

Approval History

• February 1, 2013 — EMA approval (Lyxumia)
• July 27, 2016 — FDA approval (Adlyxin)
• 2017 — Soliqua/Suliqua fixed-dose combo with insulin glargine approved
• January 2023 — Sanofi discontinues US sales of standalone Adlyxin

Place in Therapy

In jurisdictions where it remains marketed, lixisenatide is positioned as:

• Mealtime postprandial glucose control — particularly when added to basal insulin
• Adjunct to insulin for postprandial coverage — primary use case in many guidelines
• Lower-cost GLP-1 option in price-sensitive markets

In the US, the once-weekly options (semaglutide, dulaglutide) and the GLP-1/GIP dual agonist tirzepatide have largely supplanted lixisenatide. The combination product Soliqua remains relevant where titrating basal insulin and GLP-1 simultaneously is clinically useful.

Distinction from Exenatide

Lixisenatide and exenatide both derive from exendin-4 (the parent molecule from Heloderma suspectum venom), but they are distinct molecular entities:

Both molecules are now off the US market for commercial reasons; both remain part of fixed-dose combination products or international markets.

Safety Profile

The adverse event profile mirrors the GLP-1 class: nausea (most common, dose-titration dependent), vomiting, diarrhea, and injection-site reactions. Boxed warnings carried by some other GLP-1 agonists (thyroid C-cell tumor warning) apply by class; pancreatitis risk is monitored.